A recent report authored by Peter McCullough, MD, and Jessica Rose, PHD, MSc, BSc, has shown that younger people are at a higher risk for myocarditis following the Covid-19 vaccine.
Myocarditis is an inflammation of the myocardium – the heart muscle. It can reduce the heart’s ability to pump or cause abnormal heart rhythms, and severe myocarditis can weaken the heart so the body doesn’t get enough blood, which can lead to clots forming in your heart, potentially leading to a stroke or heart attack. Symptoms of myocarditis include chest pain, rapid or irregular heartbeats, or shortness of breath.
Younger people are at a higher risk for myocarditis than older groups, with the high-risk age population, reportedly being from puberty through to early 30s.
The report, titled “A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products”, analysed data from the US Vaccine Adverse Event Reporting System (VAERS) in which patients had suffered from myocarditis following the Pfizer, Moderna and Johnson & Johnson Covid jabs.
The researchers found that: “A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products.
“Within 8 weeks of the public offering of COVID-19 products to the 12-15-year-old age group, we found 19 times the expected number of myocarditis cases in the vaccination volunteers over background myocarditis rates for this age group.”
Additionally, the report states that a 5-fold increase in the rate of myocarditis was observed subsequent to the second dose as opposed to a single dose in 15-year-old males. A total of 67% of these cases took place following the Pfizer vaccine. The report found that out of the total myocarditis cases, 6 individuals died, of these, two were under 20 years of age – one of whom was 13.
